Evidence map›Paper›PMID 38256026›Full record

ArticleInternational journal of molecular sciences2024

Expressions of HuR, Methyl-HuR and Phospho-HuR in Endometrial Endometrioid Adenocarcinoma Are Associated with Clinical Features.

Judicaël Hotton, Guillaume Gauchotte, Romane Mougel, Mégane Migliorini, Stéphanie Lacomme, Shyue-Fang Battaglia-Hsu, Mikaël Agopiantz

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Judicaël HottonDepartment of Gynecology and Obstetrics, CHRU de Nancy, Université de Lorraine, 54000 Nancy, France.
Guillaume GauchotteINSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.ORCID 0000-0001-5585-9195
Romane MougelINSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.ORCID 0000-0001-7654-8150
Mégane MiglioriniINSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.
Stéphanie LacommeCentre de Ressources Biologiques, BB-0033-00035, CHRU de Nancy, 54000 Nancy, France.
Shyue-Fang Battaglia-HsuINSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.ORCID 0000-0002-5881-6251
Mikaël AgopiantzINSERM U1256 NGERE, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.ORCID 0000-0001-5192-8923
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HuR regulates cytoplasmic mRNA stability and translatability, with its expression correlating with adverse outcomes in various cancers. This study aimed to assess the prognostic value and pro-oncogenic properties of HuR and its post-translational isoforms methyl-HuR and phospho-HuR in endometrial adenocarcinoma. Examining 89 endometrioid adenocarcinomas, we analyzed the relationship between HuR nuclear or cytoplasmic immunostaining, tumor-cell proliferation, and patient survival. HuR cytoplasmic expression was significantly increased in grade 3 vs. grade 1 adenocarcinomas (

Indexed as

Carcinoma, EndometrioidELAV-Like Protein 1Endometrial NeoplasmsCell ProliferationCytoplasmCytosolFemaleHumansELAV-Like Protein 1cancerendometrial adenocarcinomaendometriumHuRimmunohistochemistrymethyl-HuRphospho-HuR

Identifiers

PMID38256026
PMCPMC10815350
OpenAlexW4390831410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.